tbuckley/cabot-search huggingface dataset:
PTH-021 Reassessing The Value of Gastroscopy for The Investigation of Dyspepsia
Authors: H-L Ching, MF Hale, R Sidhu, ME McAlindon
Journal: Gut (2016)

<h3>Introduction</h3> The National Institute of Health and Clinical Excellence (NICE) first recommended a policy of <i>H. pylori</i> test and treat or empirical full dose proton pump inhibitor therapy for uninvestigated dyspepsia in 2004.<sup>1</sup> Following an initial fall in demand for gastroscopy (OGD), there has been a 30% increase in the last five years.<sup>2</sup> Whilst regarded as the gold standard, it is uncomfortable, costly, may require sedation and carries the risks of intubation. In an era when non-invasive tests are emerging, the role of OGD requires re-evaluation. <h3>Methods</h3> Data from consecutive OGDs performed between September 2015 and January 2016 to investigate dyspepsia was analysed. We determined the percentage of patients in whom OGD ± biopsy changed management as defined by an approach other than the non-invasive NICE recommendations.<sup>1</sup> <h3>Results</h3> 500 patients (39.8% male; mean age 58±16.1) underwent OGD for dyspepsia, some of whom also had dysphagia (6%), anaemia (4%), vomiting (4.2%) or suspected gastrointestinal (GI) bleeding (0.6%). 145 (29%) were sedated (midazolam (mean±SEM) 2.0 mg±1.0; fentanyl (when used) 50 mcg±23). 381 patients (76.2%) had abnormal endoscopy; 417 (83.4%) had biopsies taken (15.8% for histological assessment, 27.4% for rapid urease tests, 40.2% for both). Findings of uncertain relevance, or which could have been managed with empirical therapies, were seen in 299 patients (59.8%; including oesophagitis (n = 122), hiatus hernias (n = 178), gastric polyps (n = 34), gastritis (n = 236), gastric ulcers (n = 9), gastric erosions (n = 32), duodenitis (n = 40), duodenal ulcer (n = 1), duodenal erosions (n = 15) and a duodenal polyp (n = 1)). Diagnoses which would not have been appropriately managed by empirical therapies numbered 82 (16.4%). These included 71 (14.2%) patients with Barrett’s oesophagus (n = 39), oesophageal stricture (n = 2), oesophageal cancer (n = 1) and gastric cancer (n = 4) diagnosed at the time of endoscopy. An additional 11 (2.2%) diagnoses were made solely by histology, which included eosinophilic oesophagitis (n = 1), eosinophilic gastritis (n = 1), intestinal metaplasia (n = 3) and coeliac disease (n = 6). <h3>Conclusion</h3> Diagnoses which alter management are made by endoscopy in only 14.2% of patients with dyspepsia. Although the majority of patients have biopsies taken, the added value increases the yield to only 16.4%. Non-invasive, cost-effective diagnostic strategies are needed to better guide patient management and select the minority of patients who need endoscopic biopsy or therapy. <h3>References</h3> 1 www.nice.org.uk/guidance/CG184 (2014 update) 2 https://www.england.nhs.uk/statistics <h3>Disclosure of Interest</h3> None Declared
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease
Authors: Juan-Jesus Carrero, Christoph Varenhorst, Karin Jensevik, Karolina Szummer, Bo Lagerqvist, Marie Evans, Jonas Spaak, Claes Held, Stefan James, Tomas Jernberg
Journal: Kidney International (2016)
Metastatic Merkel cell carcinoma response to nivolumab
Authors: Frances M. Walocko, Benjamin Y. Scheier, Paul W. Harms, Leslie A. Fecher, Christopher D. Lao
Journal: Journal for ImmunoTherapy of Cancer (2016)

Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC.We report a case of a patient with metastatic MCC with a significant and durable response to nivolumab, a humanized IgG4 monoclonal anti-PD-1 antibody.Immunotherapy with PD-1/PD-L1 inhibitors has become a rational and promising treatment option for MCC in the advanced or metastatic disease. Clinical trials are currently in progress to further evaluate these novel therapeutic agents.
HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis
Authors: Joshua A Hill, Sophia Koo, Belisa Guzman Suarez, Vincent T Ho, Corey Cutler, John Koreth, Philippe Armand, Edwin P Alyea, Lindsey R Baden, Joseph H. Antin, Robert J Soiffer, Francisco M Marty
Journal: Blood (2011)
Trends in Research Publications About Gun Violence in the United States, 1960 to 2014
Authors: Ted Alcorn
Journal: JAMA Internal Medicine (2016)

The response to firearm injuries and gun violence in the United States is constrained by a lack of scientific knowledge.According to a 2013 report from the Institute of Medicine, "the scarcity of research on firearm-related violence limits policymakers' ability to propose evidence-based policies that reduce injuries and deaths and maximize safety." 1 In the 1980s, the Centers for Disease Control and Prevention initiated research on firearm injuries, but, in 1996, Congress forbid the agency from spending funds to "advocate or promote gun control." 2 Its spending on firearm injury research fell 96% by 2012, 3 and the agency retreated from the subject.To assess trends in scientific research on the association between guns, crimes, and violence, this study examined changes over time in the number of published articles and the number of researchers writing them.As publications are a major means for the dissemination of scientific knowledge, their volume can serve as a measure of scientific attention.
THU0385 Patient and Physician Agreement in All Bath Ankylosing Spondylitis Disease Activity Index Questions Is Excellent except for Enthesitis
Authors: L. Ghukasyan, A. Moltό, A. Etcheto, M. Dougados
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The BASDAI is a validated and widely used instrument to assess disease activity in SpA. Despite being a self-administered questionnaire, in daily practice, physicians often ask the questions themselves to the patients. To the authors best knowledge no data has been reported evaluating the agreement between patient and physician for the BASDAI. <h3>Objectives</h3> To assess the agreement between patients and physicians reported BASDAI in axial SpA patients in daily practice. <h3>Methods</h3> Patients with axial SpA according to the treating rheumatologist were included. First, patients were asked to fill out the BASDAI questionnaire in the waiting room. Thereafter, and being unaware of the results reported by the patients, the rheumatologist collected another BASDAI by reading out loud the questions to the patient and giving explanations if needed. Agreement for the total score and for each question was calculated by the intraclass correlation coefficient and its 95%CI. Evaluation of the agreement for the axial BASDAI (i.e. removing questions 3 and 4) was performed identically. <h3>Results</h3> Fifty patients were included, aged 44 (±10) y and 32 (64%) males. Mean disease duration was 15 (±10) y and among them 34 (69,4%) had a radiographic sacroiliitis. Agreement between patient and physician was excellent both for the BASDAI and axial BASDAI: ICC 0.91 [95% CI, 0.84–0.95] and ICC 0.94 [95% CI, 0.90–0.97], respectively. The lowest agreement was found for question 4 (i.e. referring to enthesitis) with an ICC [95%CI] =0.51 [0.28 – 0.69]. <h3>Conclusions</h3> An excellent agreement was found between patients and physicians for the BASDAI and its axial version. However, the question for enthesitis yielded only a moderate agreement, even in a group of patients with long-standing disease, and therefore used to fill this questionnaire. This should encourage physicians to use BASDAI as a self-administered questionnaire. <h3>Acknowledgement</h3> This research was conducted while the first author Liana Ghukasyan was an ARTICULUM Fellow. <h3>Disclosure of Interest</h3> None declared
Estimated GFR Derived From Plasma Creatinine by Mass Spectrometry (MSMS) Is A Reliable Measure of Renal Function During the Hyperfiltration Phase In Sickle Cell Disease (SCD)
Authors: Baba Inusa, Caroline Booth, Charles Turner, Helen Appleby, Giselle Padmore-Penniston, R. Neil Dalton
Journal: Blood (2010)
The Prognostic Value of JAK2 Exon 16 Mutations in Children with Down Syndrome and Acute Lymphoblastic Leukemia.
Authors: T. Buitenkamp, A. A. Danen-van Oorschot, M. Van Den Heuvel-Eibrink, E. van Wering, R. Pieters, C. M Zwaan
Journal: Blood (2008)
Proteomic Profiling of Multiple Myeloma Plasma Cells and Normal Plasma Cells Reveals Differential Expression of Clu1 and Basp1 Proteins
Authors: Dominik Dytfeld, Malathi Kandarpa, Stephanie J Kraftson, John R Strahler, Dattatreya Mellacheruvu, Suchitra Subramani, Alexey Nesvizhskii, Andrzej J Jakubowiak
Journal: Blood (2010)
Resistance to Annexin A5 Anticoagulant Activity and Specificity for Anti-B2GPI Domain I Antibodies in Obstetric Antiphospholipid Syndrome
Authors: Beverley J Hunt, Xiao-Xuan Wu, Bas de Laat, Alan A Arslan, Kiran Parmar, Sarah Stuart-Smith, Jacob H Rand
Journal: Blood (2008)
The Presence and Number of Activatory KIR (R+D−) Impact the Infection and Survival Status of Patients Transplanted with an HLA Matched Sibling Donor.
Authors: Pascale Loiseau, Chun Chen, Marie-Lorraine Appert, Vanderson Rocha, Marc Busson, Alain Filion, Virginia Lepage, Antoine Toubert, Eliane Gluckman, Dominique Charron
Journal: Blood (2004)
PCSM-07SYMPTOM BURDEN OF PATIENTS IN FOLLOW-UP FOR PRIMARY BRAIN TUMOR
Authors: Anna Leisy, Terri Armstrong, Stanley Cron
Journal: Neuro-Oncology (2015)

BACKGROUND: Primary Brain Tumor (PBT) patients present with symptoms unique from other solid tumor patients because of the location in the central nervous system. After completing therapy they are considered to be in follow-up but are never considered to be in remission because of the high rate of recurrence. The purpose of this study is to compare the symptom experience of patients in follow-up (FU) for PBT with those of patients undergoing active treatment (OT). METHODS: Cross-sectional patient-reported outcome (PRO) symptom data was obtained on outpatients at MD Anderson Cancer Center. The survey tool used was the M.D.Anderson Symptom Inventory-Brain Tumor which measures both core oncology and PBT-specific symptoms. OT and FU groups were compared for each of the 22 symptom items. Symptom item scores were also categorized as low or moderate/severe. Aggregate scores were also obtained for six functional symptom groupings. Group comparisons by symptom item were conducted with the chi-square test, while the t test for independent samples was used to compare aggregate scores. FINDINGS: 446 patients (216 OT and 230 FU) were included in the sample. No significant demographic differences were found between treatment and follow-up groups. The sample was primarily white (82.9%) and male (58.5%). Mean symptom severity was not significantly different between groups [OT 1.52 (0-7.35), FU 1.75 (0-6.82), p = 0.09]. No significant difference between groups was found in frequency of moderate/severe symptoms for 20 of 22 items. It was found that follow up patients reported more moderate/severe difficulty with remembering (p = 0.0087) and drowsiness (p = 0.0157). CONCLUSION: This preliminary analysis shows that patients in follow-up for PBT have a symptom burden that is as significant as patients who are receiving treatment for active disease. Additional research is needed to determine factors that explain symptom pattern or severity over time.
Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes
Authors: Aisha N. Hasan, Rosanna J. Ricafort, Annamalai Selvakumar, Ekaterina Doubrovina, Isabelle Riviere, Michel Sadelain, Richard J. O'Reilly
Journal: Blood (2012)
Regulation of An Acquired Inhibitor to the GPVI Platelet Collagen Receptor in a Patient with An Autoimmune Syndrome and Kidney Disease.
Authors: Paquita Nurden, Narendra Tandon, Hisao Takizawa, Xiaoqi Gong, Alice Conception, Delphine Morel, Pierre Merville, Sebastien Loya, Martine Jandrot-Perrus, Alan T. Nurden
Journal: Blood (2008)
AB0319 Analysis of Large Joint Destruction in Patients with Rheumatoid Arthritis Treated by Golimumab
Authors: K. Kanbe, K. Oh, J. Chiba
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> There is no investigation of large joint destruction treated with golimumab in rheumatoid arthritis. Especially what clinical factors related to the inhibition of large joint destruction was not reported so far. <h3>Objectives</h3> In order to investigate the inhibition of large joint destruction for rherumatoid arthritis in treated with golimumab, 450 large joints were assessed at baseline and 52 weeks after treatment with golimumab. <h3>Methods</h3> 450 large joints from 45 patients including elbow, shoulder, hip, knee and ankle by using ARASHI (Assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) scoring system (1) at baseline and 52 weeks after treatment with golimumab. Baseline data were mean age of 61.29±14.71 years, 91.1% of female, mean disease duration of 12.6±12.48 years, stage/class of I:7,II:10,III:9:,IV:19/2:18,3:26,4:1, mean MTX of 6.44±1.78 mg/weeks, mean PSL of 1.078±1.871 mg/day, 44.4% of 100 mg for golimumab, mean DAS28 (CRP) of 4.431±1.044. Rapid radiographic progression (RRP) and rapid radiographic improvement (RRI) were calculated and analysis of correlation for large joint destruction and clinical factors between baseline and 52 weeks. <h3>Results</h3> RRP was 21.9% in 450 large joints treated with golimumab. Therefore 78.1% were inhibited large joint destruction treated with goimumab in RA. RRI was 35.7% showing large joint improvement were obtained by golimumab. In clinical factors, baseline CRP affects ARASHI change score of knee at 52 weeks after treatment of golimumab. <h3>Conclusions</h3> Inhibition of large joint destruction were obtained in 78.1% for the patients treated with golimumab in RA. <h3>References</h3> Kaneko A, et al. Development and validation of a new radiographic scoring system to evaluate bone and cartilage destruction and healing of large joints with rheumatoid arthritis: ARASHI (Assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) study. Modern Rheumatology 23:1053–62, 2013. <h3>Disclosure of Interest</h3> None declared
FRI0349 A Survival Analysis of Patients with Primary Sjögren's Syndrome
Authors: V. Yazisiz, M. Göçer, S. Oygen, A.B. Avci, E. Gökalp, E. Terzioğlu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Primary Sjögren9s syndrome (pSS) is a systemic autoimmune disease with unknown aetiology and involves mainly salivary and lacrimal glands. It is an autoimmune disease with a broad range of systemic manifestations. Mortality rate might reduce in pSS patients with treated new medications. There is no information on survival of pSS patients in our country. <h3>Objectives</h3> This study was conducted to determine clinical features and survival in pSS patients <h3>Methods</h3> All pSS patients who diagnosed betwen 2004–2014 years were included in this study. The clinical and laboratory features and mortality rates were reevaluated <h3>Results</h3> There were 718 patients with suspected pSS at 10 years. 372 patients were classified as pSS according to 2012 American Collage of Rheumatology Classification Criteria for Sjögren9s Syndrome. Women/men ratio was 11/1. The mean age at the time of diagnosis was 50.3±11.81 years. 14 patients (3.8%) were diagnosed different malignancy and 18 patients died (4.8%). The rate of 10-year survival was 95.6% (%96.6 for women, %86.6 for men, p:0.004). 10-year survival rate was % 98.7 in patients without pulmonary involvement, but 79.2% in patients with pulmonary involvement. Multivariate Cox analysis showed that pulmonary involvement (OR:12.8, %95 CI: 4.52–44.8, p&lt;0.001) and male gender (OR:1.7%95, CI: 1.17–4.53, p=0.004) were independent mortality risk factors <h3>Conclusions</h3> Our data revealed that cumulative survival was 95.6% at 10 years in pSS patients. Pulmonary involvement represented the main cause of death. pSS patients with pulmoner involvement have greater risk of death. <h3>Disclosure of Interest</h3> None declared
Pre-Clinical Data and Preliminary Patient Results of Intravenous MV-NIS To Treat Relapsed, Refractory Multiple Myeloma.
Authors: Angela Dispenzieri, Rae M. Myers, Caili Tong, Suzanne M. Greiner, Mary E. Harvey, Guy Griesmann, Joel Reid, Mark Federspiel, Matthew M. Ames, David Dingli, Martha Q. Lacy, Morie A. Gertz, Karen Schweikwart, Anthony Welch, Kah-Whye Peng, Stephen J. Russell
Journal: Blood (2007)
Left Ventricular Function Declines with Increasing Myocardial Ferritin Iron in Thalassemia Major.
Authors: Sujit Sheth, Haiying Tang, Jens H. Jensen, Karen Altmann, Ashwin Prakash, Beth F. Printz, Anthony L. Brown, Allan J. Hordof, Christina L. Tosti, Andjela Azabagic, Srirama Swaminathan, Truman R. Brown, Nancy F. Olivieri, Gary M. Brittenham
Journal: Blood (2005)
Leukemia in Breast Cancer Patients Following Adjuvant Chemotherapy or Postoperative Radiation
Authors: Bernard Fisher, Howard Rockette, Edwin R. Fisher, D. Lawrence Wickerham, Carol Redmond, Ann Brown
Journal: Journal of Clinical Oncology (1986)

In the article by Fisher et al in the December 1985 issue (Leukemia in Breast Cancer Patients Following Adjuvant Chemotherapy or Postoperative Radiation: The NSABP Experience, J Clin Oncol 3:1640–1658, 1985), an error was made in the body and notes of Table 1 (page 1642). References made to "cyclophosphamide parvum" should have read "Coryne bacterium parvum."
Dietary Hypercholesterolemia Enhances Heparin-Induced Thrombocytopenia/Thrombosis: A Prothrombotic Risk Factor in a Transgenic Mouse Model.
Authors: Michael P. Reilly, Scott K. Dessain, Scott M. Taylor, M. Anna Kowalska, Mortimer Poncz, Bruce S. Sachais, Douglas B. Cines, Gowthami Arepally, Kevin Jon Williams, Steven E. McKenzie
Journal: Blood (2005)
Rosalind Mary Maskell
Authors: Juan C Mason
Journal: BMJ (2016)

“The work of Rosalind Maskell is unknown to many; yet, clearly ahead of her time, she performed scientifically rigorous studies that provided compelling evidence to disprove the dogma that urine was sterile in the absence of a clinically relevant infection.” This accolade appears in a 2015 AJOG paper entitled “The new world of the urinary microbiota in women” from the Loyola University Urinary Research Collaboration, Chicago. Although the identification of bacteria by modern DNA sequencing techniques was unavailable to her research in the 1970s and 80s, Rosalind Maskell did pioneer the use of expanded urine culture methods, which are now recognised as an important component of urinary infection analysis.

Initially inclined to the arts, it was perhaps the influence of her mother, A G Rewcastle (the first …
A Recent Update of Three Consecutive Prospective Trials with High-Dose Therapy and Autograft, without or with Rituximab, as Primary Treatment for Advanced-Stage Follicular Lymphoma (FL) Shows a Sizeable Group of Patients Surviving in Continuous Complete Remission up to 16 Years After the End of Treatment: Should We Still Consider FL An Incurable Disease ?.
Authors: Corrado Tarella, Marco Ladetto, Fabio Benedetti, Umberto Vitolo, Alessandro Pulsoni, Caterina Patti, Vincenzo Callea, Alessandro Rambaldi, Andrea Piccin, Michele Magni, Maurizio Musso, Emilio Iannitto, Pierangelo Spedini, Anna Marina Liberati, Fabio Ciceri, Andrea Gallamini, Francesco Rodeghiero, Guido Gini, Alberto De Crescenzo, Francesco Di Raimondo, Alessandro Levis, Teodoro Chisesi, Tommasina Perrone, Delia Rota Scalabrini, Giuseppe Rossi, Angelo Michele Carella, Guido Parvis, Ignazio Majolino, Roberto Passera, Marco Ruella, Alessandro Pileri, Alessandro Gianni, Paolo Corradini
Journal: Blood (2009)
Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma
Authors: Maher K Gandhi, Frank Vari, Pauline Crooks, Colm Keane, Jamie P Nourse, Louise A Seymour, David Ritchie, David Gottlieb, Devinder Gill, Kimberley Jones
Journal: Blood (2012)
A Randomized, Double-Blind, Placebo-Controlled, Phase-2B Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients with Sepsis and Suspected Disseminated Intravascular Coagulation
Authors: Inder Kaul, Kazuhisa Tsuruta, Kenneth Gorelick, Yutaka Osawa, Debra Hoppensteadt, Jawed Fareed, Jean-Louis Vincent
Journal: Blood (2012)
Novel Tyrosine Kinase Inhibitor Therapy (NTKI) Prior to Allogeneic Stem Cell Transplantation (ASCT) in Patients with Chronic Myeloid Leukemia (CML): No Evidence for Increased Transplant-Related Toxicity.
Authors: Elias Jabbour, Jorge Cortes, Hagop Kantarjian, Sergio Giralt, Francis Giles, Borje S. Andersson, Richard Champlin, Marcos de Lima
Journal: Blood (2006)
Role of the Somatic Mutation Rate in Patients with Classical Myeloproliferative Neoplasms (MPN) with and without Other Neoplasms
Authors: Margherita Berardi, Tommaso Rondelli, Maria Chiara Susini, Annamaria Pellecchia, Elisabetta Antonioli, Luca Boni, Lucio Luzzatto, Alessandro M. Vannucchi, Rosario Notaro
Journal: Blood (2012)
Bcl2 Expression Predicts Better Overall Survival in 90 Patients with Mantle Cell Lymphoma.
Authors: Carsten Schrader, Wolfram Klapper, Dirk Janssen, Paul Riis, Peter Meusers, Guenter Brittinger, Jens U. Siebmann, Michael Kneba, Reza Parwaresch
Journal: Blood (2005)
Reduction of Hepatic Iron in Patients with Thalassemia Major According to Iron Chelation Regime Assessed by MRI T2*
Authors: Vassilios Ladis, Giorgos Chouliaras, Kirikos Zannikos, Panagiotis Moraitis, Eleni Berdoussi, Vasilios Antonios Berdoukas
Journal: Blood (2008)